Editorial: New Advances in Non-small Cell Lung Cancer Management: Immune Modulation and Targeted Therapies

Código QR

Editorial: New Advances in Non-small Cell Lung Cancer Management: Immune Modulation and Targeted Therapies

Guardado en:

Detalles Bibliográficos
Autores principales:	Thierry Berghmans, Jacques Cadranel, Bogdan Grigoriu
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	lung immunotherapy targeted therapy PD1 PDL1 Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/2fa75af771a94c05a28495da8dc61426
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
por: Virginia Liberini, et al.
Publicado: (2021)

Immunotherapy for the Treatment of Breast Cancer: Emerging New Data
por: Mina LA, et al.
Publicado: (2020)

Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review
por: Matthieu Roulleaux Dugage, et al.
Publicado: (2021)

Emerging Therapies for Advanced Cholangiocarcinoma: An Updated Literature Review
por: Anthony Vignone, et al.
Publicado: (2021)

Immunotherapeutic Advances for NSCLC
por: Massafra M, et al.
Publicado: (2021)

Adverse Events Induced by PD-1/PD-L1 Inhibitors: A Real-World Single-Centre Experience with a Management-Based Approach
por: Grimaud F, et al.
Publicado: (2021)

Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters
por: Gaurav Garg, et al.
Publicado: (2021)

Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives
por: Denis I. Yudin, et al.
Publicado: (2021)

Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma
por: Pei-Yi Chu, et al.
Publicado: (2021)

Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
por: Kyoichi Kaira, et al.
Publicado: (2021)

Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
por: Chuan HUANG, et al.
Publicado: (2021)

New targeted treatments for non-small-cell lung cancer – role of nivolumab
por: Zago G, et al.
Publicado: (2016)

Molecular genetic portrait of non-small cell lung cancer in Tambov region: regional experience
por: N. A. Ognerubov, et al.
Publicado: (2020)

Adjuvant targeted therapy for non-small cell lung cancer
por: Konstantin K. Laktionov, et al.
Publicado: (2020)

Real-world treatment practice in patients with advanced melanoma
por: Bożena Cybulska-Stopa, et al.
Publicado: (2020)

Prospects for the development of adjuvant therapy for non-small cell lung cancer
por: K. K. Laktionov, et al.
Publicado: (2020)

Analysis of lung cancer measures of the National Cancer Network pilot study in Poland for potential improvement in the quality of advanced-stage lung cancer therapy
por: Łukasz Trembecki, et al.
Publicado: (2021)

A cellular census of human peripheral immune cells identifies novel cell states in lung diseases
por: Dongli Song, et al.
Publicado: (2021)

Tumor Lysis Syndrome following a Single Dose of Nivolumab for Relapsed Small-Cell Lung Cancer
por: Sarah Maryon Hayes, et al.
Publicado: (2021)

Dl-3-N-Butylphthalide Presents Anti-Cancer Activity in Lung Cancer by Targeting PD-1/PD-L1 Signaling
por: Jiang Q, et al.
Publicado: (2021)

Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden
por: Parikh AR, et al.
Publicado: (2018)

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
por: Xin Cai, et al.
Publicado: (2021)

Nanomaterials Enhance the Immunomodulatory Effect of Molecular Targeted Therapy
por: Li Z, et al.
Publicado: (2021)

Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer
por: Matteo Canale, et al.
Publicado: (2021)

Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2
por: Damian Mojsak, et al.
Publicado: (2021)

Treatment of Advanced Metastatic Melanoma
por: Pietro Quaglino, et al.
Publicado: (2021)

New Aspects of Ultrasound-Mediated Targeted Delivery and Therapy for Cancer
por: Tian Y, et al.
Publicado: (2020)

Treatment of advanced small cell lung cancer. Clinical case and literature review
por: Konstantin V. Menshikov, et al.
Publicado: (2021)

The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis
por: He Ba, et al.
Publicado: (2021)

Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
por: Galina B. Statsenko, et al.
Publicado: (2020)

Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy
por: Chenlu Li, et al.
Publicado: (2021)

Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis
por: Yang You, et al.
Publicado: (2021)

Gender Differences and Immunotherapy Outcome in Advanced Lung Cancer
por: Tiziana Vavalà, et al.
Publicado: (2021)

Molecular Characterization of the Clinical and Tumor Immune Microenvironment Signature of 5-methylcytosine-Related Regulators in non-small Cell Lung Cancer
por: Taisheng Liu, et al.
Publicado: (2021)

Clinical Trial Progress and Application of Immune Checkpoint Inhibitors  in the Treatment of Small Cell Lung Cancer
por: Huiqiu ZHANG, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non–Small Cell Lung Cancer: Emerging Mechanisms and Perspectives
por: Inoue H, et al.
Publicado: (2020)

Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
por: Tan AC, et al.
Publicado: (2021)

Immunotherapy-Related Cardiotoxicity Re-Emergence in Non-Small Cell Lung Cancer – A Case Report
por: Li Y, et al.
Publicado: (2021)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
por: Miao Wang, et al.
Publicado: (2021)

Chemokine Pathways in Cutaneous Melanoma: Their Modulation by Cancer and Exploitation by the Clinician
por: Rebecca Adams, et al.
Publicado: (2021)